89 related articles for article (PubMed ID: 10455428)
1. A role for intracellular immunization in chemosensitization of tumor cells?
Pich A; Rancourt C
Gene Ther; 1999 Jul; 6(7):1202-9. PubMed ID: 10455428
[TBL] [Abstract][Full Text] [Related]
2. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM; de Vries EG; de Jong S
Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy developments for pancreatic cancer.
Bhattacharyya M; Lemoine NR
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):285-98. PubMed ID: 16549328
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis.
Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
Curr Opin Investig Drugs; 2002 Apr; 3(4):641-7. PubMed ID: 12090737
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.
Hersey P; Zhuang L; Zhang XD
Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779
[TBL] [Abstract][Full Text] [Related]
10. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
Capalbo G; Rödel C; Stauber RH; Knauer SK; Bache M; Kappler M; Rödel F
Strahlenther Onkol; 2007 Nov; 183(11):593-9. PubMed ID: 17960333
[TBL] [Abstract][Full Text] [Related]
11. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
13. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
15. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
[TBL] [Abstract][Full Text] [Related]
16. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma.
Sanlioglu AD; Aydin C; Bozcuk H; Terzioglu E; Sanlioglu S
Lung Cancer; 2004 May; 44(2):199-211. PubMed ID: 15084385
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
18. The role of antisense oligonucleotides in the treatment of bladder cancer.
Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
[TBL] [Abstract][Full Text] [Related]
19. The role of survivin as a new target of diagnosis and treatment in human cancer.
Yamamoto T; Tanigawa N
Med Electron Microsc; 2001 Dec; 34(4):207-12. PubMed ID: 11956993
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]